Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 108Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Leukemia 15Lymphoma 14Burkitt Lymphoma 14Recurrence 10Lymphoma, Non-Hodgkin 10Lymphoma, Mantle-Cell 10Waldenstrom Macroglobulinemia 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Immunoglobulin Light-chain Amyloidosis 8Neoplasms, Plasma Cell 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Smoldering Multiple Myeloma 5Neoplasms 5Lymphoma, Follicular 5Leukemia, Biphenotypic, Acute 5Hodgkin Disease 5Neoplasm Metastasis 4Nausea 4Breast Neoplasms 4Vomiting 3Renal Insufficiency 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Plasma Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 3Brain Neoplasms 3Blast Crisis 3

Interventions

Vincristine 2Methotrexate 2Mercaptopurine 2Hydrocortisone 2Cytarabine 2prednylidene 1pegaspargase 1merphos 1hydrocortisone hemisuccinate 1dexamethasone acetate 1dexamethasone 21-phosphate 1calaspargase pegol 1blinatumomab 1azathiopurine 1auricularum 1Spinal Puncture 1Specimen Handling 1Radiotherapy, Conformal 1Prednisolone 1Nivolumab 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Epirubicin 1Dexamethasone 1Daunorubicin 1Cyclophosphamide 1Calcium Dobesilate 1Biopsy 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Down Syndrome × Calcium Dobesilate × Clear all
NCT04546399 2025-09-10

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

National Cancer Institute (NCI)

Phase 2 Recruiting
461 enrolled
Lymphoid

Burkitt Lymphoma, Down Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡